Arvinas, Inc. (ARVN)
Nasdaq: ARVN · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2015
Who owns Arvinas, Inc.
As filed with the SECHolders of 5% or more
2
Blackrock, Inc. holds 7.9% of Common Stock, as its SCHEDULE 13G/A filed Apr 17, 2025 says.
Directors and officers
12
report now, of 24 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
D. E. Shaw & Co., L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common stock, par value $0.001 per share · reported falling below 5%, from 5.3% in Nov 14, 2025
Logos Global Management LP
SCHEDULE 13D/A · filed Oct 15, 2025 · Common Stock ("Stock") · reported falling below 5%, from 8.6% in Aug 22, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Aug 14, 2025 · COMMON STOCK · reported falling below 5%
Kenneth Griffin
SCHEDULE 13G/A · filed Nov 14, 2025 · Common stock, par value $0.001 per share (the "Shares") · reported falling below 5%, from 5.1% in Feb 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 12.2% in Apr 30, 2025
EcoR1 Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock · reported falling below 5%
What ARVN reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Oerth Bio Limited Liability Corporation
An entity · co registrant · owns, named in the 10-K filed Feb 24, 2026
Oerth Bio Limited Liability Corporation
An investee · investee, legal entity · invested in, named in the 10-K filed Feb 24, 2026
4 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 24, 2026.
Insider tradesForm 4
23sales
1purchases
3sales on a scheduled plan
6people selling
$1.4Msold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Nov 9, 2025 to Nov 9, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 9, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 44 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Houston John G | President and CEO | 3 | $500,000 | 0 | 0 | $0 |
| Teel Randy | President and CEO | 5 | $200,000 | 0 | 0 | $0 |
| Saik Andrew | Chief Financial Officer | 3 | $200,000 | 1 | 0 | $0 |
| Cacace Angela M | Chief Scientific Officer | 5 | $200,000 | 1 | 0 | $0 |
| Berkowitz Noah | Chief Medical Officer | 3 | $200,000 | 0 | 0 | $0 |
| Morrison Briggs | director | 0 | $0 | 0 | 1 | $300,000 |
| Loomis David K | VP, Chief Accounting Officer | 4 | $0 | 1 | 0 | $0 |